Pricing Log in Create free account
Saturday 17 October 2026 Export GDRX’s income statement to Excel — free account

GoodRx Holdings, Inc.

GDRX Healthcare Health Information Services

GoodRx Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $796.9 million, up 0.57% from fiscal 2024. In the quarter to June 2026, revenue fell 1.31%, EPS fell 25.0%, free cash flow grew 112.5% and total debt was flat, each against the same quarter a year earlier.

3.36 0.15 −4.27%
Market cap
$1.2B
P/E
62.7×
Fwd P/E
30.9×
Dividend yield
—
F-score
6/9
Altman Z
0.44
Beneish M
−2.40
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 9.68
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — 2 — —
Insider Ownership 73.99%

Capital & Financial Ratios $m

Market Cap 1,200.00
Revenue 785.23
Net Income 16.25
Free Cash Flow 131.70
Net Debt 190.48
Current Ratio 1.38
Debt/Equity 0.75
P/E ratio 62.69 (above 35: high)
Fwd P/E 30.90
P/S ratio 1.45
P/B ratio 1.76
Past 5Y EPS Growth —
This Y EPS Growth (13.33%) (below 0%: weak)
Next Y EPS Growth 15.79% (at or above 15%: strong)
Next Y revenue growth 0.18%
Next 5Y EPS Growth 5.83%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.7×, against a ten-year median of 3.0×; over the ten years it ranged from 1.1× in 2026 to 27.6× in 2021.
P/S against its own 10 years 13.39%
10-year low 10-year high
P/B against its own 10 years 12.90%
10-year low 10-year high
EV/Sales against its own 10 years 13.25%
10-year low 10-year high
EV/FCF against its own 10 years 3.28%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 672 448 262 296
Receivables 144 146 236 182
Inventory — — — —
Other — 23 98 1,076
873 659 643 1,599
2023 2024 2025 Q'26
Payables 36 14 19 9
ST’ Debt 9 5 5 5
Other — 16 130 1,040
123 124 246 1,158

Compound Annual Growth %

10y 5y 3y
Sales — 7.67% 1.30%
Cash Flow — 5.03% 4.58%
Earnings — 0.00% 0.00%
Book Value — (2.83%) (8.89%)

Revenue $m

Mar Jun Sep Dec Year
’26 194 200 — — —
’25 203 203 196 195 797
’24 198 201 195 199 792
’23 184 190 180 197 750
’22 203 192 187 184 767
’21 160 177 195 213 745
’20 133 123 140 154 551
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 12 81 — — —
’25 9 50 76 33 168
’24 43 10 87 45 184
’23 32 30 60 16 138
’22 30 51 34 32 147
’21 45 35 49 50 179
’20 46 38 33 15 131
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (10) 66 — — —
’25 (12) 31 58 17 94
’24 22 (8) 71 28 114
’23 18 15 47 3 83
’22 18 37 20 17 92
’21 36 28 40 41 144
’20 42 33 15 5 96
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.00 0.02 — — —
’25 0.03 0.04 0.00 0.02 0.09
’24 0.00 0.02 0.01 0.02 0.04
’23 (0.01) 0.14 (0.09) (0.06) (0.02)
’22 0.03 0.00 (0.10) 0.00 (0.08)
’21 0.00 0.07 (0.04) (0.10) (0.06)
’20 0.12 0.12 (0.21) (1.09) (1.07)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 33.51 26.66 3.82 4.14 4.09 2.61

Analyst estimates 2026–2028

Powerpack
High — — — — 64.22 59.67 33.15 9.37 9.26 5.81
People
People Employees — — — 338 478 777 954 694 738 697
Revenue/emp, $m 0.00 0.00 0.00 1.15 1.15 0.96 0.80 1.08 1.07 1.14
Income, $m
Income, $m Revenue 99 157 250 388 551 745 767 750 792 797
Gross margin, % 89.62 92.26 97.58 96.39 94.63 93.73 91.51 91.08 93.91 92.77
EBT 15 40 52 83 (303) (10) (23) (56) 31 57
EBT margin, % 15.20 25.25 20.98 21.37 (55.10) (1.37) (3.03) (7.41) 3.97 7.10
Net income (8) 0 44 66 (294) (25) (33) (9) 16 30
Depreciation — — 11 17 22 38 58 111 72 87
Per share, $
Per share, $ Revenue 0.26 0.41 2.23 1.71 2.00 1.82 1.86 1.83 2.05 2.24
Earnings (0.02) 0.02 0.39 0.29 (1.07) (0.06) (0.08) (0.02) 0.04 0.09
Cash flow 0.00 0.00 0.40 0.37 0.48 0.44 0.36 0.34 0.48 0.47
Capex 0.00 0.00 (0.03) (0.03) (0.13) (0.08) (0.13) (0.14) (0.18) (0.21)
Free cash flow 0.00 0.00 0.37 0.34 0.35 0.35 0.22 0.20 0.29 0.26
Book value 0.02 (0.22) (3.80) (1.55) 2.59 2.03 1.97 1.86 1.88 1.73
Shares, m 385 385 112 227 275 410 413 410 386 356
Valuation, ×
Valuation, × P/E 138.66 138.66 138.66 138.66 0.00 0.00 0.00 0.00 98.10 30.04
P/S 24.64 24.64 24.64 24.64 20.12 17.97 2.54 3.07 2.26 1.21
P/B 0.00 0.00 0.00 0.00 15.58 16.11 2.39 3.03 2.48 1.57
EV/Sales 25.93 25.93 25.93 25.93 19.57 17.60 2.41 3.05 2.32 1.50
EV/FCF 79.93 79.93 79.93 79.93 112.82 90.91 20.16 27.75 16.18 12.70
Cash, $m
Cash, $m Operating cash flow — — 45 83 131 179 147 138 184 168
Capex — — (3) (6) (36) (34) (55) (56) (70) (74)
Free cash flow — — 42 78 96 144 92 83 114 94
Balance, $m
Balance, $m Working capital — — 56 53 1,027 1,008 843 750 535 397
Total debt 46 136 722 671 667 663 659 656 492 488
Net debt 22 118 688 645 (305) (278) (98) (16) 43 226
Shareholders’ equity 8 (86) (425) (351) 711 832 815 762 725 616
Returns, %
Returns, % ROA (2.67) 5.98 4.66 12.19 (31.62) (1.64) (2.04) (0.56) 1.10 2.18
ROIC 0.00 0.00 18.41 29.66 (42.37) 1.51 0.15 (2.26) 5.36 6.49
ROE 3.77 (4.29) (2.01) (3.80) 156.09 (3.27) (3.99) (1.12) 2.21 4.54
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

GoodRx Holdings, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SDGR Schrodinger, Inc. $1.9B — (loss-making) — (loss-making) +7.54% (above 0%: growing) n/m +34.43% (above 0%: growing) 55.07% (70.55%) Compare
OMCL Omnicell, Inc. $1.6B 41.6× 55.1× +7.45% (above 0%: growing) +341.67% (above 0%: growing) +107.90% (above 0%: growing) 48.98% 10.39% Compare
CERT Certara, Inc. $1.5B — (loss-making) — (loss-making) +0.99% (above 0%: growing) n/m −78.46% (below 0%: shrinking) 62.34% (0.21%) Compare
GDRX GoodRx Holdings, Inc. $1.2B 62.7× 30.9× −1.31% (below 0%: shrinking) −25.00% (below 0%: shrinking) +112.45% (above 0%: growing) 89.52% 11.79%
OMDA Omada Health, Inc. $1.1B 252× 143× +43.12% (above 0%: growing) n/m +45.71% (above 0%: growing) 72.62% 4.04% Compare
TDOC Teladoc Health, Inc. $1.1B — (loss-making) — (loss-making) −3.95% (below 0%: shrinking) n/m −27.07% (below 0%: shrinking) 68.56% (6.11%) Compare
HSTM HealthStream, Inc. $1.0B 46.0× 34.4× +12.55% (above 0%: growing) +27.78% (above 0%: growing) +362.71% (above 0%: growing) 65.35% 9.94% Compare
PHR Phreesia, Inc. $685.3M 64.4× 23.5× +10.41% (above 0%: growing) +200.00% (above 0%: growing) +43.51% (above 0%: growing) 66.64% 5.88% Compare
MDRX Veradigm Inc. $654.5M — (loss-making) — (loss-making) −9.74% (below 0%: shrinking) n/m −66.33% (below 0%: shrinking) 50.53% (37.41%) Compare
Median of peers $1.1B 55.2× 44.8× +7.49% +200.00% +38.97% 63.85% 1.92%

All 51 Health Information Services stocks →

GoodRx Holdings, Inc. (GDRX) key facts

  • Strength: GoodRx Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $796.9 million, up 0.57% from fiscal 2024.
  • GoodRx Holdings, Inc. (GDRX) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, GDRX traded at $3.36, a market capitalization of $1.2 billion.
  • Return on equity was 4.54% and debt-to-equity 0.75.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 0.44 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

GoodRx Holdings, Inc. (GDRX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/GDRX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com